- Home
- Publications
- Publication Search
- Publication Details
Title
Chimeric antigen receptor T-cell therapies for lymphoma
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 15, Issue 1, Pages 31-46
Publisher
Springer Nature
Online
2017-08-31
DOI
10.1038/nrclinonc.2017.128
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GLOBAL PIVOTAL PHASE 2 TRIAL OF THE CD19-TARGETED THERAPY CTL019 IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)-AN INTERIM ANALYSIS
- (2017) S.J. Schuster et al. HEMATOLOGICAL ONCOLOGY
- Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels
- (2017) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Monitoring of Serum DNA Methylation as an Early Independent Marker of Response and Survival in Metastatic Breast Cancer: TBCRC 005 Prospective Biomarker Study
- (2017) Kala Visvanathan et al. JOURNAL OF CLINICAL ONCOLOGY
- Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells
- (2017) Iulia Diaconu et al. MOLECULAR THERAPY
- Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
- (2017) Frederick L. Locke et al. MOLECULAR THERAPY
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
- (2017) Justin Eyquem et al. NATURE
- Therapeutic T cell engineering
- (2017) Michel Sadelain et al. NATURE
- Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
- (2017) Arnab Ghosh et al. NATURE MEDICINE
- Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells
- (2017) Waseem Qasim et al. Science Translational Medicine
- A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
- (2017) Dina Schneider et al. Journal for ImmunoTherapy of Cancer
- CAR-T Cell Therapy for Lymphoma
- (2016) Carlos A. Ramos et al. Annual Review of Medicine
- T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
- (2016) S. A. Ali et al. BLOOD
- Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL
- (2016) X. Wang et al. BLOOD
- Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy
- (2016) V. Jurinovic et al. BLOOD
- PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: refueling the CAR
- (2016) Elise A. Chong et al. BLOOD
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
- (2016) R. Chen et al. BLOOD
- Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies
- (2016) M. Sabatino et al. BLOOD
- Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study
- (2016) E Van Den Neste et al. BONE MARROW TRANSPLANTATION
- 2016 US lymphoid malignancy statistics by World Health Organization subtypes
- (2016) Lauren R. Teras et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Driving gene-engineered T cell immunotherapy of cancer
- (2016) Laura A Johnson et al. CELL RESEARCH
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma
- (2016) M. Ruella et al. CLINICAL CANCER RESEARCH
- Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial
- (2016) Chun-Meng Wang et al. CLINICAL CANCER RESEARCH
- Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
- (2016) Leonid Cherkassky et al. JOURNAL OF CLINICAL INVESTIGATION
- Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
- (2016) Carlos A. Ramos et al. JOURNAL OF CLINICAL INVESTIGATION
- CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
- (2016) Cameron J. Turtle et al. JOURNAL OF CLINICAL INVESTIGATION
- Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
- (2016) Partow Kebriaei et al. JOURNAL OF CLINICAL INVESTIGATION
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies
- (2016) Marco Ruella et al. JOURNAL OF CLINICAL INVESTIGATION
- Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
- (2016) Jennifer N. Brudno et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
- (2016) Philippe Armand et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- 74. The Impact of Different Hinge and Transmembrane Components on the Function of a Novel Fully-Human Anti-CD19 Chimeric Antigen Receptor
- (2016) Leah M. Alabanza et al. MOLECULAR THERAPY
- Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
- (2016) Mark J Osborn et al. MOLECULAR THERAPY
- GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
- (2016) Tessa Gargett et al. MOLECULAR THERAPY
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
- (2016) Cameron J. Turtle et al. Science Translational Medicine
- High-density preculture of PBMCs restores defective sensitivity of circulating CD8 T cells to virus- and tumor-derived antigens
- (2015) J. Wegner et al. BLOOD
- Immune checkpoint blockade in hematologic malignancies
- (2015) P. Armand BLOOD
- Secondary malignancies following high dose therapy and autologous hematopoietic cell transplantation-systematic review and meta-analysis
- (2015) I Vaxman et al. BONE MARROW TRANSPLANTATION
- Global cancer statistics, 2012
- (2015) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells
- (2015) Zeguo Zhao et al. CANCER CELL
- Designing chimeric antigen receptors to effectively and safely target tumors
- (2015) Michael C Jensen et al. CURRENT OPINION IN IMMUNOLOGY
- CAR therapy: the CD19 paradigm
- (2015) Michel Sadelain JOURNAL OF CLINICAL INVESTIGATION
- Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study
- (2015) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
- (2015) James N. Kochenderfer et al. JOURNAL OF CLINICAL ONCOLOGY
- Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2015) Craig H Moskowitz et al. LANCET
- T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
- (2015) Daniel W Lee et al. LANCET
- PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study
- (2015) Alison J Moskowitz et al. LANCET ONCOLOGY
- The pharmacology of second-generation chimeric antigen receptors
- (2015) Sjoukje J. C. van der Stegen et al. NATURE REVIEWS DRUG DISCOVERY
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adoptive cell transfer as personalized immunotherapy for human cancer
- (2015) S. A. Rosenberg et al. SCIENCE
- Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
- (2015) David L. Porter et al. Science Translational Medicine
- Functional Tuning of CARs Reveals Signaling Threshold above Which CD8+ CTL Antitumor Potency Is Attenuated due to Cell Fas-FasL-Dependent AICD
- (2015) A. Kunkele et al. Cancer Immunology Research
- Mantle cell lymphoma: evolving management strategies
- (2014) Elias Campo et al. BLOOD
- Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
- (2014) S. M. Horwitz et al. BLOOD
- Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
- (2014) I. W. Flinn et al. BLOOD
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells
- (2014) Yao Wang et al. CLINICAL IMMUNOLOGY
- Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
- (2014) Saar Gill et al. IMMUNOLOGICAL REVIEWS
- Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
- (2014) Michelle A. Fanale et al. JOURNAL OF CLINICAL ONCOLOGY
- Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
- (2014) Shannon L. Maude et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
- (2014) M. L. Davila et al. Science Translational Medicine
- Relapsed Hodgkin Lymphoma: Management Strategies
- (2014) Francesca Montanari et al. Current Hematologic Malignancy Reports
- Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era
- (2013) Sarah J. Nagle et al. AMERICAN JOURNAL OF HEMATOLOGY
- Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
- (2013) J. N. Kochenderfer et al. BLOOD
- Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: Results of the National LymphoCare Study
- (2013) Peter Martin et al. CANCER
- Diffuse large B-cell lymphoma
- (2013) Maurizio Martelli et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Single-Agent Lenalidomide in Patients With Mantle-Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: Phase II MCL-001 (EMERGE) Study
- (2013) Andre Goy et al. JOURNAL OF CLINICAL ONCOLOGY
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
- (2013) Mathias J Rummel et al. LANCET
- Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
- (2013) Anas Younes et al. LANCET ONCOLOGY
- Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors
- (2013) James N. Kochenderfer et al. Nature Reviews Clinical Oncology
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
- (2013) Michael L. Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- CD19 CAR-Targeted T Cells Induce Long-Term Remission and B Cell Aplasia in an Immunocompetent Mouse Model of B Cell Acute Lymphoblastic Leukemia
- (2013) Marco L. Davila et al. PLoS One
- Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
- (2013) Lihua E. Budde et al. PLoS One
- CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
- (2013) R. J. Brentjens et al. Science Translational Medicine
- The Basic Principles of Chimeric Antigen Receptor Design
- (2013) Michel Sadelain et al. Cancer Discovery
- Lessons learned from a highly-active CD22-specific chimeric antigen receptor
- (2013) Adrienne H. Long et al. OncoImmunology
- Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
- (2012) W. Haso et al. BLOOD
- CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
- (2012) B. G. Till et al. BLOOD
- Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur
- (2012) Christian H. Geisler et al. BRITISH JOURNAL OF HAEMATOLOGY
- Brentuximab Vedotin
- (2012) C. Deng et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT
- (2012) A Spyridonidis et al. LEUKEMIA
- B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
- (2011) J. N. Kochenderfer et al. BLOOD
- Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation
- (2011) Claire Roddie et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
- (2011) Barbara Savoldo et al. JOURNAL OF CLINICAL INVESTIGATION
- Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the European Group for Blood and Marrow Transplantation Registry
- (2011) Roel J.W. van Kampen et al. JOURNAL OF CLINICAL ONCOLOGY
- Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
- (2011) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors
- (2011) David Telio et al. LEUKEMIA & LYMPHOMA
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
- (2011) M. Kalos et al. Science Translational Medicine
- Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
- (2010) Michael C. Jensen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells
- (2010) J. N. Kochenderfer et al. BLOOD
- Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group
- (2010) N. Schmitz et al. BLOOD
- Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95
- (2010) Audrey Simon et al. BRITISH JOURNAL OF HAEMATOLOGY
- Rituximab in Hodgkin lymphoma: Is the target always a hit?
- (2010) Kamal S. Saini et al. CANCER TREATMENT REVIEWS
- Response to Second-line Therapy Defines the Potential for Cure in Patients With Recurrent Diffuse Large B-Cell Lymphoma: Implications for the Development of Novel Therapeutic Strategies
- (2010) Rebecca L. Elstrom et al. Clinical Lymphoma Myeloma & Leukemia
- Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
- (2010) Christian Gisselbrecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
- (2010) Renier Brentjens et al. MOLECULAR THERAPY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapse after Allogeneic Hematopoietic Cell Therapy
- (2009) Marcel R.M. van den Brink et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Down-regulation of CD20 expression in B-cell lymphoma cells after treatment with rituximab-containing combination chemotherapies: its prevalence and clinical significance
- (2009) J. Hiraga et al. BLOOD
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model
- (2009) A. Di Stasi et al. BLOOD
- The promise and potential pitfalls of chimeric antigen receptors
- (2009) Michel Sadelain et al. CURRENT OPINION IN IMMUNOLOGY
- Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study
- (2009) Andreas Engert et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244
- (2009) Peter J. Hoskin et al. JOURNAL OF CLINICAL ONCOLOGY
- Construction and Preclinical Evaluation of an Anti-CD19 Chimeric Antigen Receptor
- (2009) James N. Kochenderfer et al. JOURNAL OF IMMUNOTHERAPY
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo
- (2009) Michael C. Milone et al. MOLECULAR THERAPY
- Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains
- (2009) C. Carpenito et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Graft-versus-host disease after donor leukocyte infusions: presentation and management
- (2008) Noelle V. Frey et al. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
- Graft-versus-leukemia effects of transplantation and donor lymphocytes
- (2008) H.-J. Kolb BLOOD
- Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
- (2008) C. H. Geisler et al. BLOOD
- Non-myeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience
- (2008) Andrew R. Rezvani et al. BRITISH JOURNAL OF HAEMATOLOGY
- Utility of subsequent conventional dose chemotherapy in relapsed/refractory transplant-eligible patients with diffuse large B-cell lymphoma failing platinum-based salvage chemotherapy
- (2008) T. Seshadri et al. Hematology
- Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma
- (2008) Robert Marcus et al. JOURNAL OF CLINICAL ONCOLOGY
- Favorable Long-Term Survival After Reduced-Intensity Allogeneic Transplantation for Multiple-Relapse Aggressive Non-Hodgkin's Lymphoma
- (2008) Kirsty J. Thomson et al. JOURNAL OF CLINICAL ONCOLOGY
- Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Relapsed, Refractory, and Transformed Indolent Non-Hodgkin's Lymphoma
- (2007) Andrew R. Rezvani et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now